Therapeutic Vaccines for Autoimmune Diseases

CuraVac Europe is a clinical-stage biotechnology company focused on developing innovative Therapeutic Vaccines and Active Targeted Immunotherapies aimed at treating autoimmune diseases. Their primary research is centered on a Therapeutic Vaccine for Myasthenia Gravis (MG), a condition that disrupts the neuromuscular junction, leading to severe muscle weakness. The company employs a novel approach utilizing complementary peptides derived from the mRNA sequence of the acetylcholine receptor's main immuno region. This technique allows for the creation of complementary antibodies that can neutralize the harmful auto-antibodies targeting these receptors, thereby restoring normal muscle function without broadly suppressing the immune system, which is a common drawback of existing treatments.

CuraVac's technology has shown promise in early clinical trials, demonstrating both safety and efficacy for their MG Therapeutic Vaccine. The company aims to expand its research to other autoimmune diseases, including Multiple Sclerosis, Type 1 Diabetes, and Systemic Lupus Erythematosus, using the same complementary peptide technology. Their goal is to develop treatments that not only alleviate symptoms but potentially offer long-lasting cures, moving away from traditional maintenance therapies. This innovative approach positions CuraVac as a potential leader in the field of autoimmune disease treatment, with the ambition to significantly improve the quality of life for patients worldwide.

Belgium

CuraVac is a clinical-stage biotech developing a new class of targeted therapeutic vaccines / immunotherapies for autoimmune diseases. Our first therapeutic vaccine is for myasthenia gravis (MG). Preclinical work is ongoing for other autoimmune diseases including MS and GBS. Future studies will focus on Graves' diease, Hashimoto's disease, Type 1 Diabetes, ...

CuraVac Europe

Company Details